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Abstract	
Background	
Genome-wide	 association	 studies	 (GWAS)	 have	 identified	 94	 common	 single	
nucleotide	 polymorphisms	 (SNPs)	 associated	with	 breast	 (BC)	 and	 18	with	 ovarian	
cancer	 (OC)	 risks.	 	 Several	 of	 these	 are	 also	 associated	 with	 risk	 of	 BC	 or	 OC	 for	
women	who	carry	a	pathogenic	mutation	in	the	high-risk	BC	and	OC	genes	BRCA1	or	
BRCA2.	 The	 combined	 effects	 of	 these	 variants	 on	 BC	 or	 OC	 risk	 for	 BRCA1	 and	
BRCA2	mutation	carriers	have	not	yet	been	assessed	while	their	clinical	management	
could	benefit	from	improved	personalized	risk	estimates.		
Methods	
We	 constructed	 polygenic	 risk	 scores	 (PRS)	 using	 BC	 and	 OC	 susceptibility	 SNPs	
identified	through	population-based	GWAS:	for	BC	(overall,	oestrogen	receptor	(ER)	
positive,	 and	 ER-negative)	 and	 for	 OC.	 Using	 data	 from	 15,252	 female	BRCA1	 and	
8,211	BRCA2	carriers,	the	association	of	each	PRS	with	BC	or	OC	risk	was	evaluated	
using	 a	 weighted	 cohort	 approach	 with	 time	 to	 diagnosis	 as	 the	 outcome	 and	
estimation	of	the	hazard	ratios	(HR)	per	standard	deviation	 increase	 in	the	PRS.	All	
statistical	tests	were	two-sided.		
Results	
The	PRS	for	ER-negative	BC	displayed	the	strongest	association	with	BC	risk	in	BRCA1	
carriers	 (HR=1.27,	 95%	 confidence	 interval	 (CI):1.23-1.31,	 p=8.2x10-53).	 In	 BRCA2	
carriers,	 the	 strongest	 association	 with	 BC	 risk	 was	 seen	 for	 the	 overall	 BC	 PRS	
(HR=1.22,	95%CI:	1.17-1.28,	p=7.2x10-20).	 The	OC	PRS	was	 strongly	associated	with	
OC	risk	for	both	BRCA1	and	BRCA2	carriers.	These	translate	to	differences	in	absolute	
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risks	(more	than	10%	in	each	case)	between	the	top	and	bottom	deciles	of	the	PRS	
distribution,	 e.g.,	 the	 OC	 risk	 was	 6%	 by	 age	 80	 for	 BRCA2	 carriers	 at	 the	 10th	
percentile	of	the	OC	PRS	compared	with	19%	risk	for	those	at	the	90th	percentile	of	
PRS.	
Conclusions	
BC	 and	 OC	 PRS	 are	 predictive	 of	 cancer	 risks	 in	 BRCA1	 and	 BRCA2	 carriers.	
Incorporation	 of	 the	 PRS	 into	 risk	 prediction	models	 has	 promise	 to	 better	 inform	
decisions	on	cancer	risk	management.	
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Introduction	
Women	who	carry	a	pathogenic	mutation	in	the	BRCA1	or	BRCA2	gene	are	at	
high	 risk	 of	 developing	 breast	 and	 ovarian	 cancers.	 The	 clinical	 management	 of	
healthy	women	with	a	BRCA1	or	BRCA2	mutation	involves	a	combination	of	frequent	
screening,	 risk-reducing	 surgeries	 and	 chemoprevention	 (1).	 Important	 decisions	
include	whether	or	not	to	undergo	preventive	mastectomy	and	the	age	at	which	to	
undergo	 risk-reducing	 salpingo-oophorectomy	 (RRSO).	 These	 choices	 are	 invasive,	
have	substantial	 side-effects,	and	are	associated	with	adverse	psychological	effects	
(2-6).	 Improved	personalized	 cancer	 risk	 estimates	may	help	 to	 identify	women	at	
particularly	high	risk	or	with	high	risk	of	disease	at	early	ages	who	may	benefit	from	
early	 intervention	as	well	as	women	at	 lower	risk	who	may	opt	to	delay	surgery	or	
chemoprevention	(7).	This	could	be	achieved	by	incorporating	risk-modifying	factors	
into	risk	prediction.	
Population-based	 genome-wide	 association	 studies	 have	 identified	 94	
common	 breast	 and	 18	 ovarian	 cancer	 susceptibility	 loci	 (8-10).	 While	 a	 smaller	
number	 of	 these	 loci	 were	 associated	 with	 risk	 in	 BRCA1	 and	 BRCA2	 mutation	
carriers	at	stringent	statistical	significance	thresholds,	the	effect	sizes	in	carriers	are	
generally	 similar	 to	 those	 in	 the	 general	 population,	 once	 differences	 in	 the	
distributions	of	breast	tumor	estrogen	receptor	status	in	mutation	carriers	and	non-
carriers	are	taken	into	account	(9,	11).	Individually	the	identified	breast	and	ovarian	
cancer	 risk-modifying	 variants	 confer	 only	 small	 to	 modest	 increases	 in	 risk.	
However,	their	effects	can	be	combined	into	polygenic	risk	scores	(PRS),	which	may	
be	 associated	 with	 much	 larger	 relative	 risks	 (12,	 13).	 Prior	 to	 the	 clinical	
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implementation	of	 these	 findings,	 it	 is	 important	 to	 assess	 the	predictive	 utility	 of	
PRS	in	terms	of	discrimination,	calibration,	and	potential	for	risk	stratification	(14).	
Because	women	with	BRCA1	and	BRCA2	mutations	are	already	at	high	risk	of	
developing	 breast	 and	 ovarian	 cancers,	 the	 combined	 effects	 of	 risk-modifying	
variants	could	lead	to	much	larger	differences	in	the	absolute	risk	of	developing	the	
disease	 as	 compared	 with	 the	 general	 population	 (12,	 13,	 15,	 16).	 Earlier	 studies	
investigating	 the	 effect	 of	 PRS	 on	 the	 absolute	 risks	 of	 breast	 and	 ovarian	 cancer	
risks	 of	 BRCA1	 and	 BRCA2	 mutation	 carriers	 demonstrated	 potential	 for	 risk	
stratification	(13,	17-19).	However,	these	have	been	based	on	small	numbers	of	SNPs	
(<15)	 and	 most	 were	 restricted	 to	 theoretical	 projections	 of	 the	 PRS	 association	
rather	than	empirical	evaluations.			
In	this	study	we	developed	different	PRS	for	breast	and	ovarian	cancer	as	well	
as	 oestrogen	 receptor	 (ER)-specific	 PRS	 based	 on	 reported	 susceptibility	 loci	 from	
population-based	studies,	and	evaluated	their	associations	with	risks	for	BRCA1	and	
BRCA2	carriers.	We	estimated	absolute	risks	of	developing	breast	and	ovarian	cancer	
for	individuals	with	different	values	of	the	PRS	in	order	to	assess	whether	these	PRS	
provide	clinically	useful	risk	stratification	of	mutation	carriers.	
	
	
Methods	
Study	population	
Eligible	 study	 subjects	 included	 in	 the	 Consortium	 of	 Investigators	 of	
Modifiers	of	BRCA1/2	(CIMBA)	are	female	carriers	of	a	pathogenic	mutation	in	either	
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BRCA1	or	BRCA2	who	are	≥18	years	of	age.	Mutation	carriers	were	recruited	by	56	
study	centers	 in	26	countries.	The	majority	were	recruited	through	cancer	genetics	
clinics,	 and	 enrolled	 into	 national	 or	 regional	 studies.	We	 used	 data	 from	 15,252	
BRCA1	 (breast	 cancer=7,797;	 ovarian	 cancer=2,462)	 and	 8,211	 BRCA2	 (breast	
cancer=4,330;	ovarian	cancer=631)	mutation	carriers	who	were	genotyped	with	the	
iCOGS	 array.	 Quality	 control	 has	 been	 described	 in	 detail	 elsewhere	 (11,	 13,	 18).	
Each	of	 the	host	 institutions	 recruited	mutation	 carriers	under	protocols	 approved	
by	 local	 ethics	 review	 boards.	 Written	 informed	 consent	 was	 obtained	 from	 all	
subjects.	Only	samples	of	European	ancestry	were	included	in	the	present	analysis.	
	
Polygenic	risk	scores	
The	 effects	 of	 cancer	 susceptibility	 variants	 on	 cancer	 risks	 for	 mutation	
carriers	were	combined	into	PRS.	The	PRS	for	individual	i	was	defined	as	the	sum	of	
the	 number	 of	 risk	 alleles	 across	 k	 variants	 weighted	 by	 the	 effect	 size	 of	 each	
variant:	𝑃𝑅𝑆$ = 𝛽'𝑔'$ + ⋯+ 𝛽+𝑔+$ 	
where	𝑔,$ 	 is	the	genotype	of	person	 i	for	variant	 l,	expressed	as	the	number	
of	effect	alleles	(0,1,	or	2)	and	𝛽, 	 is	the	per-allele	 log	risk	ratio	(Odds	Ratio	(OR)	or	
Hazard	 Ratio	 (HR),	 Supplementary	 Tables	 1-6)	 associated	with	 the	 effect	 allele	 of	
SNP	l.		
The	primary	PRS	were	based	on	SNPs	found	to	be	associated	with	breast	or	
ovarian	cancer	through	GWAS	in	the	general	population.	For	breast	cancer,	we	used	
the	 published	 PRS	 for	 overall	 breast	 cancer,	 ER-positive	 breast	 cancer	 and	 ER-
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negative	 breast	 cancer	 (8,	 20).	 In	 addition,	 we	 created	 updated	 PRS	 based	 on	
findings	 from	 population-based	 association	 and	 fine-mapping	 studies	 reported	
before	 April	 2015	 (Supplementary	 Table	 1)	 (8,	 10,	 21-28).	 More	 details	 on	 the	
variant	selection	are	provided	in	the	Supplementary	Methods.	
We	 developed	 an	 ovarian	 cancer	 PRS	 by	 including	 the	 most	 strongly	
associated	 variant	 from	 each	 region	 associated	 at	 genome-wide	 statistical	
significance	level	with	ovarian	cancer	risk	in	population-based	studies	or	studies	that	
combined	population	data	and	data	from	mutation	carriers	(Supplementary	Table	2)	
(9,	23).		
We	 also	 constructed	 secondary	 BRCA1-	 and	 BRCA2-specific	 PRS	 that	 were	
based	on	all	variants	showing	evidence	of	association	in	BRCA1	and	BRCA2	carriers,	
using	 the	 results	and	weights	 from	the	BRCA1-	 and	BRCA2-specific	GWAS	 	 (11-13).	
(Supplementary	 Tables	 3-6,	 Supplementary	Methods).	 However,	 the	 studies	 that	
led	 to	 the	 identification	 of	 these	 variants	were	 based	 on	 the	 same	 dataset	 as	 the	
present	 analysis.	 Therefore,	 these	 BRCA1-	 and	 BRCA2-specific	 PRS	 cannot	 be	
independently	validated	in	the	present	analysis.	To	reduce	the	bias	from	overfitting,	
we	also	constructed	and	evaluated	unweighted	versions	of	these	PRS.		
For	the	SNPs	included	in	each	PRS,	we	assessed	whether	there	was	evidence	
for	pairwise	interactions	(Supplementary	Methods).	
	
Statistical	analysis	
To	account	for	the	non-random	sampling	of	mutation	carriers	with	respect	to	
disease	 status,	 the	 association	 of	 each	 PRS	with	 breast	 or	 ovarian	 cancer	 risk	was	
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analysed	 using	 a	 weighted	 cohort	 Cox-regression	 with	 time	 to	 breast	 or	 ovarian	
cancer	 diagnosis,	 respectively,	 as	 the	 outcome	 (29)	 (Supplementary	 Methods	
[Please	 be	 specific—Supplementary	 Methods,	 Results,	 or	 a	 particular	
table/figure?).	We	evaluated	 the	associations	of	 the	breast	cancer	PRS	 (i.e.	overall	
breast	 cancer	 PRS,	 ER-positive	 PRS	 and	 ER-negative	 PRS)	 with	 the	 risk	 for	 overall	
breast	cancer	for	BRCA1	and	BRCA2	mutation	carriers.	The	ovarian	cancer	PRS	was	
assessed	for	association	with	the	risk	of	developing	overall	ovarian	cancer	for	BRCA1	
and	BRCA2	mutation	carriers.	For	these	analyses,	subjects	were	categorised	into	PRS	
percentile	 groups.	 To	 provide	 easily	 interpretable	 associations,	 the	 association	
analyses	were	repeated	using	continuous	PRS	predictors	standardised	to	have	mean	
0	and	variance	1.	We	assessed	whether	the	HR	per	unit	of	the	PRS	varied	with	age	by	
including	a	term	for	the	interaction	of	the	standardised	PRS	with	age.	We	also	fitted	
a	Cox-regression	that	included	separate	PRS	effects	by	age	group.	
To	 evaluate	 the	 ability	 of	 the	 PRS	 to	 discriminate	 between	 individuals	
developing	 breast	 or	 ovarian	 cancer	 at	 different	 ages,	 we	 computed	 the	 rank	
Harrell’s	c	index	(30)	(Supplementary	Methods).		
Absolute	age-specific	cumulative	risks	of	developing	breast	or	ovarian	cancer	
at	 different	 percentiles	 of	 the	 standardised	 PRS	 were	 calculated	 according	 to	 the	
approach	described	previously	(15,	31)	(Supplementary	Methods).	
Analyses	were	carried	out	in	R	using	GenABEL		(32)		and	in	STATA	v13.1	(33).		
Detailed	methods	are	provided	in	Supplementary	Methods.	
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Results	
PRS	associations	with	cancer	risks		
Using	 data	 from	 15,252	 BRCA1	 and	 8,211	 BRCA2	 carriers	 (Supplementary	
Table	7),	there	was	no	evidence	for	interaction	between	any	two	variants	involved	in	
any	of	 the	PRS	after	accounting	 for	multiple	 testing	 (results	not	 shown).	All	breast	
cancer	PRS	derived	 from	population-based	 study	 results	 (Supplementary	Tables	1)	
were	statistically	significantly	associated	with	breast	cancer	risks	for	both	BRCA1	and	
BRCA2	 carriers	 (Table	 1).	 Compared	 with	 the	 PRS	 developed	 by	 Mavaddat	 et	 al.	
(Supplementary	Table	9),	the	updated	breast	cancer	PRS	displayed	slightly	stronger	
associations	in	BRCA1	carriers	but	no	improvements	were	seen	in	BRCA2	carriers.		
The	 PRS	 for	 ER-negative	 breast	 cancer	 displayed	 the	 strongest	 association	
with	 breast	 cancer	 risk	 in	 BRCA1	 carriers	 (per-standard-deviation	 (SD)	 HR=1.27,	
95%CI:	 1.23-1.31,	 p=8.2x10-53)	 (Table	 1).	 Smaller	 HR	 estimates	 in	 BRCA1-breast	
cancer	were	seen	for	the	PRS	for	overall	breast	cancer	(HR=1.14,	95%CI:	1.11-1.17,	
p=1.8x10-18)	and	ER-positive	breast	cancer	(HR=1.11,	95%CI:	1.08-1.15,	p=3.5x10-13).	
In	BRCA2	carriers,	the	ER-negative	breast	cancer	PRS	displayed	a	smaller	per-SD	HR	
for	breast	cancer	risk	 (HR=1.15,	95%CI:	1.10-1.20,	p=6.8x10-10)	compared	to	BRCA1	
carriers	whereas	the	overall	breast	cancer	PRS	(HR=1.22,	95%CI:	1.17-1.28,	p=7.2x10-
20)	 and	 the	 ER-positive	 PRS	 (HR=1.22,	 95%CI:	 1.16-1.27,	 p=4.0x10-19)	 displayed	
stronger	associations.	The	subsequent	breast	cancer	analyses	focus	on	the	updated	
ER-negative	 breast	 cancer	 PRS	 for	 BRCA1	 carriers	 and	 the	 updated	 overall	 breast	
cancer	PRS	for	BRCA2	carriers.		
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Consistent	with	the	above	models,	there	were	clear	trends	in	risk	by	PRS	for	
both	BRCA1	and	BRCA2	carriers	when	PRS	was	categorised	by	percentile	 (Table	2).	
The	HR	estimates	were	consistent	with	those	predicted	by	the	model	 in	which	PRS	
was	fitted	as	a	continuous	covariate	(Figure	1).		
We	 also	 investigated	 whether	 the	 associations	 for	 the	 most	 strongly	
associated	PRS	differ	by	mutation	type,	as	defined	by	the	mutation	functional	effect	
(Supplementary	Methods).	There	was	marginal	evidence	of	an	interaction	between	
the	breast	cancer	risk	PRS	and	class	2	mutations	in	BRCA2	mutation	carriers	(p=0.03,	
with	a	slightly	higher	HR	estimate	for	the	PRS	for	class	2	mutation	carriers).		
The	 population-based	 ovarian	 cancer	 PRS	 was	 strongly	 associated	 with	
ovarian	 cancer	 risk	 in	BRCA1	 carriers	 with	 a	 per-SD	 HR	 of	 1.28	 (95%CI:	 1.22-1.34,	
p=2.5x10-26)	(Table	1).	The	HR	estimate	was	 larger	for	ovarian	cancer	risk	 in	BRCA2	
carriers:	 HR=1.49	 (95%CI:	 1.34-1.65,	 p=8.5x10-14).	 When	 we	 compared	 the	 HR	
estimates	against	the	HRs	predicted	under	a	multiplicative	polygenic	model,	only	the	
HR	estimate	for	BRCA2	carriers	for	the	60-80%	category	was	statistically	significantly	
higher	than	the	predicted	value	(Figure	1).		
The	 unweighted	 BRCA1-	 and	 BRCA2-specific	 PRS	 for	 breast	 and	 ovarian	
cancer,	 constructed	 on	 the	 basis	 of	 association	 results	 in	 CIMBA,	 showed	 strong	
evidence	of	association	with	breast	and	ovarian	cancer	(Supplementary	Table	10).		
	
PRS	x	age	interaction	
There	 was	 evidence	 for	 a	 PRSxage	 interaction	 for	 the	 ER-negative	 breast	
cancer	PRS	 for	BRCA1	 carriers	 (p=3x10-6)	 and	 for	 the	overall	 breast	 cancer	PRS	 for	
BRCA2	 carriers	 (p=0.01)	 (Table	 3).	 In	 the	 ovarian	 cancer	 analysis,	 a	 statistically	
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significant	 interaction	 with	 age	 was	 seen	 for	 the	 ovarian	 cancer	 PRS	 for	 BRCA1	
carriers	 (p=0.003).	 Each	of	 these	PRS	 showed	 stronger	associations	 in	 younger	age	
groups.		
	
Discrimination	
The	ER-negative	PRS	had	the	highest	value	of	Harrell's	c,	c=0.58	(95%CI:	0.57-
0.59),	 for	 breast	 cancer	 in	 BRCA1	 carriers	 (Table	 4).	 For	 breast	 cancer	 in	 BRCA2	
carriers,	 the	 highest	 values	 for	 Harrell's	 c	 were	 achieved	 by	 the	 population-based	
overall	and	ER-positive	breast	cancer	PRS	with	values	of	c=0.56	(95%CI:	0.55-0.58)	in	
each	case.	For	ovarian	cancer,	the	OC-PRS	had	c=0.58	(95%CI:	0.56-0.60)	for	BRCA1	
carriers	and	c=0.63	(95%CI:	0.60-0.67)	for	BRCA2	carriers.		
	
Predicted	absolute	risks	by	PRS	percentile	
We	 used	 the	 age-specific	 HR	 estimates	 to	 compute	 absolute	 cumulative	
breast	and	ovarian	cancer	risks	for	mutation	carrier	by	PRS	percentiles	(Figure	2).	We	
used	 the	updated	ER-negative	PRS	 to	predict	breast	 cancer	 risk	 for	BRCA1	 carriers	
and	 the	updated	overall	breast	 cancer	PRS	 to	predict	breast	 cancer	 risk	 for	BRCA2	
carriers.	 BRCA1	 carriers	 at	 the	 10th	 percentile	 of	 the	 PRS	 had	 a	 risk	 of	 21%	 of	
developing	breast	cancer	by	age	50	and	a	56%	risk	by	age	80.	In	contrast,	the	BRCA1	
carriers	at	the	90th	percentile	of	the	PRS	had	a	39%	breast	cancer	risk	by	age	50	and	
75%	by	age	80.	The	ovarian	cancer	risk	was	6%	by	age	80	for	BRCA2	carriers	at	the	
10th	percentile	of	 the	ovarian	cancer	PRS	compared	with	19%	 risk	 for	 those	at	 the	
90th	percentile	of	PRS.	
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Discussion	
This	is	the	first	evaluation	of	the	combined	effects	of	all	known	common	breast	and	
ovarian	 cancer	 susceptibility	 loci	on	 cancer	 risks	 for	women	who	carry	a	BRCA1	 or	
BRCA2	mutation.	We	found	strong	evidence	of	association	with	cancer	risks	for	PRS	
constructed	 using	 the	 results	 of	 population-based	 studies.	 These	 associations	
provide	strong	support	for	the	hypothesis	of	a	polygenic	component	for	breast	and	
ovarian	 cancer	 risks,	 respectively,	 that	 is	 largely	 shared	 between	 the	 general	
population	 and	 BRCA1	 and	 BRCA2	 mutation	 carriers.	 Moreover,	 the	 pattern	 of	
associations	with	the	breast	cancer	subtype-specific	PRS	confirms	the	importance	of	
tumour	ER-status	(11).	The	PRS	based	on	SNPs	associated	with	ER-negative	disease	
in	the	general	population	displayed	a	much	stronger	association	with	overall	breast	
cancer	 risk	 for	 BRCA1	 carriers	 than	 the	 ER-positive	 PRS,	 consistent	 with	 the	
observation	that	the	predominant	tumour	subtype	 in	BRCA1	carriers	 is	ER-negative	
(34,	 35).	 In	 contrast,	 the	 majority	 of	 tumours	 in	 BRCA2	 carriers	 tend	 to	 be	 ER-
positive.	 Consistent	 with	 this,	 the	 ER-positive	 PRS	 and	 the	 PRS	 for	 overall	 breast	
cancer	 constructed	 from	 general-population	 data	 exhibited	 stronger	 associations	
than	the	ER-negative	PRS	in	BRCA2	carriers.		
Using	 the	overall,	 ER-positive	and	ER-negative	breast	 cancer	PRS	developed	
by	Mavaddat,	 the	per-SD	HR	estimates	 in	mutation	carriers	were	 smaller	 than	 the	
corresponding	per-SD	OR	estimates	for	breast	cancer	in	the	population-based	study	
(20).	These	observations	suggest	that	the	relative	extent,	by	which	the	SNPs	modify	
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breast	cancer	risks	in	BRCA1	and	BRCA2	mutation	carriers	is	somewhat	smaller	than	
that	 in	 the	general	population,	perhaps	because	a	 subset	of	 SNPs	do	not	 combine	
multiplicatively	with	mutation	status.	Alternatively	these	observations	may	reflect	a	
difference	 in	 the	design:	under	a	 simple	proportional	hazards	model	 the	predicted	
odds	 ratio	 is	 larger	 than	 the	 corresponding	 rate	 ratio	 (HR),	 but	 this	 difference	 is	
usually	small	 (36).	Moreover,	some	overestimation	cannot	be	ruled	out	entirely	for	
the	per-SD	OR	estimates	 from	the	population-based	study	due	 to	a	winner’s	 curse	
effect.	 Interestingly,	 the	HR	estimate	 for	 the	association	of	 the	ovarian	cancer	PRS	
with	 ovarian	 cancer	 risk	 was	 statistically	 significantly	 higher	 for	 BRCA2	 than	 for	
BRCA1	mutation	carriers.	As	a	result,	this	PRS	had	also	a	higher	discriminatory	ability	
for	ovarian	cancer	for	BRCA2	carriers	compared	to	BRCA1	mutation	carriers.		
Each	 of	 the	 most	 strongly	 associated	 PRS	 displayed	 statistically	 significant	
interactions	 with	 age,	 with	 the	 exception	 of	 the	 ovarian	 cancer	 PRS	 in	 BRCA2	
carriers,	such	that	the	HR	per	unit	PRS	decreased	with	increasing	age.	One	possible	
explanation	 for	 the	 observed	 interaction	 between	 age	 and	 the	 ER-negative	 breast	
cancer	 PRS	 in	 BRCA1	mutation	 carriers	 could	 due	 to	 the	 use	 of	 the	 ER-negative	
breast	cancer	PRS	 from	the	general	population	 to	predict	 the	 risk	of	overall	breast	
cancer	risk	for	BRCA1	mutation	carriers.	Although	the	majority	of	breast	cancers	 in	
BRCA1	 mutation	 carriers	 are	 ER-negative,	 the	 proportion	 of	 ER-negative	 breast	
tumours	decreases	with	increasing	age	at	diagnosis	(35).	If	the	population-based	ER-
negative	 PRS	 were	 also	 associated	 primarily	 with	 ER-negative	 breast	 cancers	 in	
BRCA1	mutation	 carriers,	 the	 ER-negative	 PRS	would	 be	more	 predictive	 of	 breast	
cancer	 in	 BRCA1	 carriers	 at	 younger	 ages.	 In	 contrast,	 in	 BRCA2	 carriers	 the	
proportion	 of	 ER-positive	 disease	 was	 found	 to	 decrease	 with	 increasing	 age	 at	
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diagnosis	 (35).	 Therefore,	 the	 overall	 PRS	 from	 the	 general	 population	 which	 is	
associated	 primarily	 with	 ER-positive	 breast	 cancers,	 may	 be	 more	 predictive	 of	
breast	cancer	in	BRCA2	mutation	carriers	at	younger	ages. Alternatively,	it	is	possible	
that	genetic	risk	modification	has	a	stronger	effect	on	developing	early	onset	breast	
cancer.	
A	 limitation	 of	 the	 present	 study	 is	 our	 inability	 to	 take	 family	 history	 into	
account	 because	 this	 information	 was	 not	 available	 for	 the	 majority	 of	 samples.	
Although	 the	 tests	 of	 association	 remain	 valid,	 it	 was	 therefore	 not	 possible	 to	
investigate	how	the	associations	vary	by	family	cancer	history.		
Overall,	 the	 discrimination	 achieved	 by	 the	 PRS	 investigated	 in	 the	 current	
study	was	moderate.	The	highest	discrimination	was	achieved	by	the	ovarian	cancer	
PRS	 in	BRCA2	 carriers.	 	We	found	the	overall	breast	cancer	PRS	to	have	somewhat	
lower	 discriminatory	 ability	 in	 mutation	 carriers	 compared	 with	 the	 general	
population		(20).	However,	given	the	different	study	designs,	ER-tumour	specificity	in	
mutation	carriers	and	different	measures	of	relative	risk,	these	model-performance	
estimates	may	not	be	directly	comparable.	
One	 possible	 explanation	 for	 the	 differences	 in	 the	 relative	 risk	 of	 the	 PRS	
between	 the	 mutation	 carriers	 and	 the	 population-based	 study	 is	 that	 not	 all	
variants	 identified	 in	 population-based	 studies	 are	 actually	 associated	 with	 risk	 in	
mutation	 carriers,	 perhaps	 as	 a	 result	 of	 functional	 redundancy	 (9).	 Conversely,	
variants	 that	 specifically	modify	 risk	 in	mutation	 carriers,	 examples	 of	which	 have	
already	 been	 reported	 (13,	 18),	 would	 not	 be	 included	 in	 PRS	 derived	 from	
population-based	 studies,	 and	 such	 variants	might	 improve	 discrimination.	 On	 the	
other	hand,	because	of	the	large	sample	sizes	available	in	population-based	studies,	
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the	SNP	selection	and	the	logOR	estimates	used	as	weights	for	these	PRS	are	likely	to	
be	more	reliable	than	for	PRS	based	on	mutation	carriers.	We	also	derived	BRCA1-	
and	BRCA2-specific	PRS	that	include	variants	discovered	by	population-based	studies	
but	only	those	showing	evidence	of	association	 in	mutation	carriers.	This	approach	
makes	use	of	the	discovery	power	of	population-based	studies	while	accounting	for	
possible	 mutation-carrier-specific	 differences	 in	 associations.	 However,	 the	 SNP	
selection	and	weights	were	based	on	results	from	the	same	dataset	as	that	used	in	
the	present	 analysis.	 For	 this	 reason,	we	 investigated	 the	associations	of	mutation	
carrier-specific	PRS	without	weights	to	reduce	the	possible	overfitting.	An	analysis	in	
an	independent	sample	of	mutation	carriers	will	be	required	to	assess	whether	these	
mutation-specific	PRS	outperform	population-based	PRS.		
The	 present	 study	 demonstrates	 that	 there	 are	 large	 differences	 in	 the	
absolute	 cancer	 risks	 between	 BRCA1	 and	 BRCA2	 mutation	 carriers	 with	 higher	
versus	lower	values	of	the	PRS.	These	differences	are	much	greater	than	those	found	
in	population-based	studies	 (20,	37)	because	the	average	risks	conferred	by	BRCA1	
and	BRCA2	mutations	are	already	high	(17,	18).		The	clinical	management	of	healthy	
women	 with	 a	 BRCA1	 or	 BRCA2	 mutation	 involves	 a	 combination	 of	 frequent	
screening,	 risk-reducing	 surgery	 and	 possibly	 chemoprevention	 (1)	 which	 can	
associated	 with	 substantial	 side	 effects.	 In	 particular,	 RRSO	 leads	 to	 premature	
menopause,	 is	 associated	with	 increased	morbidity	 and	has	 implications	 for	 family	
planning	 (38,	 39).	 Therefore,	 the	 timing	 of	 RRSO	 has	 to	 be	 carefully	 considered.	
There	are	no	widely	accepted	risk	thresholds	for	RRSO	in	mutation	carriers:	RRSO	is	
recommended	 to	 all	 carriers	 on	 the	 basis	 of	 their	 average	 risk.	 The	 current	NCCN	
guidelines	recommend	RRSO	for	BRCA1	carriers	at	ages	35-40	and	BRCA2	carriers	at	
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ages	40-45	(40).	The	average	cumulative	risk	of	ovarian	cancer	by	age	40	for	BRCA1	
mutation	 carriers	 has	 been	 estimated	 as	 2.8%	 (41).	 However,	 on	 the	 basis	 of	 our	
analyses,	the	cumulative	risk	of	ovarian	cancer	for	those	at	the	lowest	1%	of	the	PRS	
by	age	40	is	predicted	to	be	0.7%,	and	20%	of	BRCA1	mutation	carriers	are	predicted	
to	have	a	 risk	of	ovarian	cancer	of	<1.3%	by	age	40.	Therefore,	 the	current	 results	
may	 be	 used	 to	 develop	 risk-based	 thresholds	 for	 RRSO	 recommendations.	 One	
possibility	 would	 be	 to	 assume	 that	 women	 with	 BRCA1	mutations	 would	 not	 be	
offered	 RRSO	 until	 their	 cumulative	 risk	 of	 ovarian	 cancer	 approaches	 or	 exceeds	
2.8%.	A	similar	rule	has	recently	been	recommended	for	the	counselling	of	women	
with	mutations	 in	moderate-risk	genes	(42).	The	ages	at	which	women	with	BRCA1	
mutations	would	reach	a	cumulative	risk	of	ovarian	cancer	of	2.8%	are	48	years	for	
those	at	the	1st	percentile	of	the	PRS,	and	46,	45,	44	and	43	years	for	those	at	the	5th	
10th,	 20th	 and	 30th	 percentile	 of	 the	 PRS,	 respectively.	For these women, deferring 
oophorectomy to these ages as opposed to the recommended ages 35-40 may be 
preferable for childbearing, and to avoid very early menopause.	 Another	 option	
would	 be	 to	 use	 risk-based	 thresholds	 defined	 for	 the	 general	 population.	 For	
example,	 a	 10%	 lifetime	 risk	 of	 ovarian	 cancer	 is	 often	 cited	 as	 a	 recommended	
threshold	for	RRSO	(43).	Based	on	our	results,	BRCA2	carriers	at	the	10th	percentile	
of	the	ovarian	cancer	PRS	have	an	estimated	6%	lifetime	risk	and	approximately	38%	
of	 BRCA2	mutation	 carriers	 have	 a	 lifetime	 risk	 of	 ovarian	 cancer	 which	 is	 <10%.		
Women	at	 this	 lower	end	of	 the	risk	spectrum	might	opt	to	delay	RRSO	to	near	or	
after	 the	 natural	 menopause,	 in	 order	 to	 avoid	 the	 harmful	 longer	 term	 adverse	
effects	of	a	surgically	induced	premature	menopause,	and	this	also	provides	a	longer	
period	 for	 child	bearing.	Therefore,	 the	PRS	may	be	 informative	 in	guiding	women	
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with	BRCA1	and	BRCA2	mutations	on	the	optimal	 timing	of	RRSO,	and	can	 identify	
women	 at	 lower	 risk	 who	 may	 opt	 for	 less	 intensive	 interventions,	 such	 as	
salpingectomy	with	delayed	oophorectomy.	
Decisions	in	relation	to	breast	cancer	prevention	could	also	be	influenced	by	
refined	risk	estimates.	For	example,	the	BRCA1	carriers	at	the	90th	percentile	of	the	
ER-negative	breast	cancer	PRS	had	an	estimated	breast	cancer	risk	of	19%	by	age	40	
and	39%	by	age	50,	compared	with	5%	by	age	40	and	21%	by	age	50	for	carriers	at	
the	10th	percentile	of	the	PRS.	As	with	RRSO,	there	are	currently	no	widely	accepted	
risk-thresholds	 for	 offering	 risk	 reducing	 bilateral	 mastectomy	 (RRBM)	 for	 women	
with	BRCA1	and	BRCA2	mutations.	However,	studies	 in	non-mutation	carriers	have	
shown	that	 the	uptake	and	timing	of	RRBM	 is	directly	 related	 to	 the	magnitude	of	
breast	cancer	risk	(44)	and	similar	arguments	may	be	applicable	to	mutation	carriers.	
To	provide	comprehensive	 risk	prediction,	 the	PRS	should	be	combined	with	other	
risk	factors,	including	family	history.	Such	a	model	would	form	the	foundation	for	the	
development	of	risk-based	clinical	management	guidelines	 for	mutation	carriers.	 In	
parallel,	 it	 will	 be	 necessary	 to	 perform	 risk	 communication	 studies	 to	 assess	 the	
acceptability	of	risk	stratification	in	women	with	BRCA1	and	BRCA2	mutations.			
In	conclusion,	the	results	demonstrate	that	these	PRS	could	be	useful	in	risk	
prediction	for	mutation	carriers.	Incorporating	these	PRS	into	risk	prediction	models	
for	 BRCA1	 and	 BRCA2	mutation	 carriers,	 together	 with	 other	 risk	 modifiers,	 may	
allow	 for	 more	 personalised	 risks	 for	 BRCA1	 and	 BRCA2	 mutation	 carriers	 and	
ultimately	facilitate	better	management	of	mutation	carriers.	 	
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Tables	
	
Table	1.	Per-standard-deviation	hazard	ratios	(HR)	and	95%	confidence	intervals	(CI)	
for	the	associations	of	polygenic	risk	scores	(PRS)	with	breast	(BC)	and	ovarian	cancer	
(OC)	risk	in	BRCA1	and	BRCA2	carriers*	
PRS	 No.	of	SNPs	
BRCA1	carriers	 BRCA2	carriers	
HR	(95%CI)	 p†	 HR	(95%CI)	 p†	
Outcome:	breast	cancer	 	 	 	 	 	
Overall	BC	PRS	 88	 1.14	(1.11-1.17)	 1.8x10-18	 1.22	(1.17-1.28)	 7.2x10-20	
ER-positive&	BC	PRS	 87	 1.11	(1.08-1.15)	 3.5x10-13	 1.22	(1.16-1.27)	 4.0x10-19	
ER-negative&	BC	PRS	 53	 1.27	(1.23-1.31)	 8.2x10-53	 1.15	(1.10-1.20)	 6.8x10-10	
Outcome:	ovarian	cancer	 	 	 	 	 	
OC	PRS	 17	 1.28	(1.22-1.34)	 2.5x10-26	 1.49	(1.34-1.65)	 8.5x10-14	
*The	 PRS	 created	 from	 the	 latest	 reported	 population-based	 study	 results	 were	
used.	†P-value	for	a	two-sided	test	using	a	weighted cohort Cox-regression with time to 
breast or ovarian cancer diagnosis, respectively, as the outcome		
&oestrogen-receptor-positive	and	-negative	
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Table	 2.	 Proportion	 of	 samples	 and	 number	 of	 events	 in	 percentile	 categories	 of	
polygenic	 risk	 scores	 (PRS)	 and	 their	 associations	 with	 breast	 and	 ovarian	 cancer	
risks*	
Percentile	category	in	%	
BRCA1	carriers	 BRCA2	carriers	
%	samples	
in	
percentile	
category	
No.	of	
events	 HR	(95%CI)†	 %	samples	in	percentile	
category	
No.	of	
events	 HR	(95%CI)†	
Outcome:	Breast	cancer	 	 	 	 	 	 	
0-5	 3.6	 222	 0.76	(0.64-0.91)	 4.0	 138	 0.80	(0.63-1.02)	
5-10	 4.1	 250	 0.70	(0.59-0.82)	 4.2	 142	 0.68	(0.54-0.87)	
10-20	 8.7	 551	 0.77	(0.68-0.87)	 8.9	 340	 0.92	(0.77-1.09)	
20-40	 18.7	 1377	 0.98	(0.89-1.07)	 18.8	 764	 1.00	(0.87-1.15)	
40-60		 20.4	 1534	 1	(reference)	 19.1	 793	 1	(reference)	
60-80	 21.0	 1729	 1.21	(1.11-1.33)	 21.2	 950	 1.16	(1.02-1.32)	
80-90	 11.0	 950	 1.32	(1.19-1.47)	 11.4	 557	 1.37	(1.17-1.60)	
90-95	 5.8	 519	 1.50	(1.31-1.72)	 5.8	 309	 1.76	(1.43-2.17)	
95-100	 6.7	 665	 1.82	(1.61-2.07)	 6.7	 337	 1.51	(1.25-1.82)	
Outcome:	Ovarian	cancer	 	 	 	 	 	 	
0-5	 4.7	 85	 0.66	(0.51-0.86)	 4.8	 20	 0.76	(0.39-1.47)	
5-10	 5.3	 110	 0.81	(0.64-1.02)	 5.3	 18	 0.67	(0.34-1.32)	
10-20	 10.5	 215	 0.80	(0.66-0.96)	 10.4	 39	 0.87	(0.54-1.39)	
20-40	 20.9	 478	 0.95	(0.82-1.10)	 20.4	 104	 1.02	(0.71-1.46)	
40-60		 19.9	 468	 1	(reference)	 20.4	 107	 1	(reference)	
60-80	 19.5	 519	 1.19	(1.03-1.38)	 19.5	 159	 1.73	(1.25-2.40)	
80-90	 9.3	 267	 1.43	(1.20-1.70)	 9.1	 76	 1.84	(1.24-2.72)	
90-95	 4.9	 155	 1.54	(1.24-1.91)	 4.8	 45	 1.87	(1.16-3.02)	
95-100	 5.1	 165	 1.86	(1.51-2.29)	 5.4	 63	 3.04	(2.00-4.61)	
*	 The	 PRS	 created	 from	 reported	 population-based	 study	 results	 were	 used.	 The	
percentile	 boundaries	 were	 derived	 assuming	 a	 normally-distributed	 PRS.	 The	
oestrogen	 receptor-negative	 breast	 cancer	 PRS	was	 used	 for	 the	 associations	with	
breast	cancer	risk	in	BRCA1	carriers	and	overall	breast	cancer	PRS	in	BRCA2	carriers.	
CI=confidence	interval;		†	 HR=hazard	 ratio	 from	 a	weighted	 cohort	 Cox-regression	 with	 time	 to	 breast	 or	
ovarian	cancer	diagnosis,	respectively,	as	the	outcome	
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Table	 3.	Age-specific	 hazard	 ratio	 (HR)	 estimates	 for	 the	 PRS	 associations	 and	 HR	
estimates	for	a	PRS	x	age	interaction*	
Age	category	
BRCA1	carriers	 BRCA2	carriers	
No.	of	
events	
HR	per	unit	SD	
increase	in	the	ER-	
PRS	
P†	 No.	of	events	
HR	per	unit	SD	
increase	in	the	
overall	BC	PRS	
P†	
Outcome:	Breast	cancer	 	 	 	 	 	 	
18-39	 4125	 1.63	(1.52-1.74)	 -	 1731	 1.65	(1.44-1.88)	 -	
40-49	 2557	 1.18	(1.13-1.23)	 4.2x10-15	 1587	 1.22	(1.14-1.31)	 8.5x10-5	
50-59	 846	 1.14	(1.09-1.21)	 0.40	 718	 1.10	(1.02-1.19)	 0.05	
≥60	 269	 1.20	(1.11-1.29)	 0.33	 294	 1.12	(1.03-1.23)	 0.75	
Interaction	HR	 	 0.993	(0.990-0.996)	 3.3x10-6	 	 0.995	(0.991-
0.999)	
0.01	
Main	effect	PRS	 	 1.69	(1.50-1.91)	 	 	 1.55	(1.29-1.87)	 	
Outcome:	Ovarian	cancer	 	 	 	 	 	 	
18-49	 1258	 1.55	(1.42-1.69)	 	 172	 3.05	(2.35-3.97)	 	
50-59	 808	 1.11	(1.05-1.18)	 1.1x10-9	 227	 1.52	(1.26-1.84)	 8.2x10-6	
≥60	 396	 1.14	(1.06-1.21)	 0.67	 232	 1.21	(1.12-1.30)	 0.03	
Interaction	HR	 	 0.992	(0.988-0.998)	 0.003	 	 0.991	(0.979-
1.00)	
0.11	
Main	effect	PRS	 	 1.83	(1.43-2.34)	 	 	 2.48	(1.34-4.58)	 	
*	 The	 population-derived	 PRS	 for	 oestrogen	 receptor-negative	 breast	 cancer	 was	
used	for	the	associations	with	breast	cancer	in	BRCA1	carriers	and	the	overall	breast	
cancer	 PRS	 in	 BRCA2	 carriers.	 P-value	 relate	 to	 the	 difference	 in	 PRS	 association	
between	each	age	group	from	the	preceding	younger	group	and	to	 the	 interaction	
term.	†	P-value	for	a	two-sided	test	using	a	weighted cohort Cox-regression with time to 
breast or ovarian cancer diagnosis, respectively, as the outcome	
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Table	4.	Discrimination	of	population-derived	polygenic	risk	scores	(PRS)	for	breast	
(BC)	and	ovarian	cancer	(OC)	in	BRCA1	and	BRCA2	carriers	
PRS	
Harrell’s	c	statistic	(95%confidence	interval)	
BRCA1	carriers	 BRCA2	carriers	
Discrimination	for	breast	cancer	 	 	
Overall	BC	PRS	 0.541	(0.530-0.551)	 0.566	(0.551-0.581)	
ER-positive	BC	PRS	 0.532	(0.522-0.543)	 0.566	(0.551-0.581)	
ER-negative	BC	PRS	 0.581	(0.571-0.592)	 0.538	(0.523-0.553)	
Discrimination	for	ovarian	cancer	 	 	
OC	PRS	 0.579	(0.559-0.600)	 0.628	(0.592-0.665)	
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Figure	legends	
Figure	1.	Hazard	ratios	(HR)	and	95%	confidence	intervals	(error	bars)	for	
percentiles	of	the	polygenic	risk	score	(PRS)	relative	to	the	middle	quintile.	The	
oestrogen	receptor-negative	breast	cancer	(BC)	PRS	(A)	and	the	overall-BC	PRS	(C)	
were	used	for	breast	cancer	in	BRCA1	and	BRCA2	carriers,	respectively,	and	the	
ovarian	cancer	(OC)	PRS	for	the	OC	associations	(B,	D).	Lines	denote	the	theoretical	
estimates	under	a	multiplicative	polygenic	model	with	means	and	standard	
deviations	of	𝑥=0.10	and	SD=0.41	for	the	ER-negative	BC	PRS,	𝑥=0.41	and	SD=0.50	
for	the	overall	BC	PRS,	𝑥=0.47	and	SD=0.37	for	the	OC	PRS.		
	
Figure	2.	Predicted	breast	cancer	risks	by	percentile	of	the	polygenic	risk	scores	
(PRS).	The	oestrogen	receptor-negative	breast	cancer	PRS	was	used	for	BRCA1	
carriers	(A)	and	the	overall	breast	cancer	PRS	for	BRCA2	carriers	(C).	Ovarian	cancer	
risks	are	given	by	percentile	of	the	ovarian	cancer	PRS	in	BRCA1	(B)	and	BRCA2	(D)	
carriers.	Age-specific	PRS	associations	were	used	to	calculate	these	cumulative	risks.	
